Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration.
- Author:
Mark J AMSBAUGH
1
;
Mehran YUSUF
;
Craig SILVERMAN
;
Jeffrey BUMPOUS
;
Cesar A PEREZ
;
Keven POTTS
;
Paul TENNANT
;
Rebecca REDMAN
;
Neal DUNLAP
Author Information
- Publication Type:Original Article
- Keywords: Sinonasal; Neoadjuvant; Organ preservation; Orbit; Exenteration
- MeSH: Disease-Free Survival; Follow-Up Studies; Humans; Orbit*; Organ Preservation*
- From:Radiation Oncology Journal 2016;34(3):209-215
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. MATERIALS AND METHODS: Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. RESULTS: Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. CONCLUSION: For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.
